← board
SNOA
distress 5/10 · elevated risk$1.16+0%today-78% from 52w high
Revenue
$20M
Liquidity
$2M
Runway
27.3 yrs
Shares 1y
+191%
Price & events
-66.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
-4.8%
1W
+1.9%
1M
-35.4%
3M
-66.1%
6M
-68.7%
1Y
-84.3%
2Y
-99.1%
5Y
-99.2%
All
Overview
- Market Cap
- $5.56M
- Volume
- 1.74K
- 52 Week Range
- $1.01 – $5.35
- Total Shares
- 4.79M
- Float Shares
- 4.77M
- Short %
- 1.73%
- % Held by Insiders
- 0.42%
- % Held by Institutions
- 1.43%
- RVOL
- 0.01x
- Beta
- 1.27
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2024-12-31partnershipAdded new distributor for wound care in UkraineSEC 8-K
- 2024-10-17partnershipExpanded distribution agreement with Medline to include Canada and OTC productsSEC 8-K
- 2024-10-01partnershipExpanded Medline partnership to Canada and OTC retailSEC 8-K
- 2024-08-01partnershipAdded Medline as US distributor for wound care productsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.